|
| Status |
Public on Dec 01, 2020 |
| Title |
HT |
| Sample type |
RNA |
| |
|
| Source name |
Diffuse large B cell lymphoma
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: HT
|
| Treatment protocol |
No treatment -- baseline measurement of gene expression without perturbation.
|
| Growth protocol |
HT and SUDHL6 cell lines were grown in Roswell Park Memorial Institute (RPMI) GlutaMAX medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Invitrogen).
|
| Extracted molecule |
total RNA |
| Extraction protocol |
GL.SOP.LAB.017 version b from Almac Diagnostics (diagnostics@almacgroup.com)
|
| Label |
biotin
|
| Label protocol |
GL.SOP.LAB.131 version b from Almac Diagnostics (diagnostics@almacgroup.com)
|
| |
|
| Hybridization protocol |
GL.SOP.LAB.131 version b from Almac Diagnostics (diagnostics@almacgroup.com)
|
| Scan protocol |
GL.SOP.LAB.131 version b from Almac Diagnostics (diagnostics@almacgroup.com)
|
| Data processing |
Standard RMA background correction, quantile normalizsation and median polish summarization (Bolstad et al 2003) on the exon and transcript core probes, resulting in log2 expression estimates. Affymetrix' Expression Console software was used, with default settings.
|
| |
|
| Submission date |
Aug 29, 2012 |
| Last update date |
Dec 01, 2020 |
| Contact name |
Barbara M Bryant |
| E-mail(s) |
barbara.bryant@constellationpharma.com
|
| Organization name |
Constellation Pharmaceuticals
|
| Street address |
215 First Street
|
| City |
Cambridge |
| State/province |
MA |
| ZIP/Postal code |
02142 |
| Country |
USA |
| |
|
| Platform ID |
GPL5175 |
| Series (2) |
| GSE40474 |
Selective lymphoma cell killing by a PRC2 small molecule inhibitor (Exon array) |
| GSE40476 |
Selective lymphoma cell killing by a PRC2 small molecule inhibitor |
|
